Inactive Instrument

Highlights Dynavax Technologies Corporation Nasdaq

Equities

US2681581029

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 01	Dynavax Technologies Corporation Announces Chief Financial Officer Changes	CI
Feb. 23	Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	Feb. 23	MT
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M	Feb. 22	MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024	Feb. 22	CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q3 Revenue $69.5M, vs. Street Est of $61.4M	Nov. 02	MT
Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023	Nov. 02	CI
Dynavax Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Dynavax Technologies Corporation Raises Revenue Guidance for the Full Year 2023	23-08-03	CI
Dynavax Technologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q2 Revenue $60.2M	23-08-03	MT
Dynavax Technologies Swings to Q1 Loss, Revenue Declines	23-05-03	MT
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q1 Revenue $46.9M, vs. Street Est of $38.6M	23-05-02	MT
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023	23-05-02	CI
Dynavax Says it Obtained Great Britain Marketing Authorization for Heplisav Hepatitis B Vaccine	23-02-28	MT
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine	23-02-28	CI
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q4 Revenue $184.5M, vs. Street Est of $178.4M	23-02-23	MT
Dynavax Technologies Corporation Provides Financial Guidance for the Full Year 2023	23-02-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dynavax Technologies Corporation Nasdaq

Equities

US2681581029

Highlights

Filters